Fisher Biosciences Adds Cellomics Technologies for High-Content Cellular Screening
News Sep 20, 2005
With the addition of Cellomics Inc., Fisher Biosciences has announced that it is providing innovative cellular-imaging tools that accelerate the drug-discovery process.
The addition of Cellomics expands Fisher Biosciences' reach into the high-content cellular-analysis field.
Some of the products that Cellomics offers include imaging systems for visualizing cellular activities, fluorescent and other high-content assays, and software applications to facilitate the interpretation of cell-screening assays.
The ability to screen for targets and drug candidates in cells provides early information on the mechanism of drug action, off-target pathway activation as well as drug safety.
"This is a great advantage for drug-discovery researchers because it provides more biologically relevant information," said Leland Foster, Chief Executive Officer of Fisher Biosciences.
"The addition of Cellomics greatly enhances our offering. By combining Cellomics cell-imaging products and services with our HyClone cell-culture, Pierce protein-chemistry and Dharmacon RNA-interference technologies, we now provide a suite of essential tools to increase the efficiency and effectiveness of our customers' research."
Fisher claims that, using Dharmacon's proprietary small-interfering RNA products, a researcher can silence the expression of any gene in the human genome and then use Cellomics tools to visualize and measure the outcome in a cellular assay.
The coupled technologies also offer the opportunity for speeding the development of structure activity and specificity relationships for other drug entities such as small molecules.
"We believe that these tools will significantly speed up the drug-discovery and development process by allowing our customers to obtain more information in less time," Foster said.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.